Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
Journal of Clinical and Nursing Research
Inhaled drug delivery is mainly used to treat pulmonary airway disorders by transporting the drug directly to its targeted location for action. This decreases the dose required to exert a therapeutic effect and minimizes any potential adverse effects. Direct drug delivery to air passages facilitates a faster onset of action; it also minimizes irritation to the stomach, which frequently occurs with oral medications, and prevents the exposure of drugs to pre-systemic metabolism that takes place in the intestine and liver. In addition to that, the lung is regarded as a route for transporting medications throughout the entire body’s blood circulation. The type of medication and the device used to deliver it are both important elements in carrying the drug to its target in the lungs. Different types of inhalation methods are used in inhaled delivery. They differ in the dose delivered, inhalation technique, and other factors. This paper will discuss these factors in more detail.
British Journal of Anaesthesia, 2000
Journal of Aerosol Medicine, 2006
Unwanted systemic absorption of drugs delivered for the local treatment of respiratory disease is well documented. Methods to minimize this now exist, especially for reduction of oropharyngeal deposition. While small molecules appear to be absorbed also from the airways, it is the alveolated regions that provide a large absorptive surface. Lung has been used as a portal for systemic delivery of substances such as anesthetics, nicotine and a number of illicit drugs. Much research has lead to the solutions of the fundamental technical hurdles of practicable delivery of systemic therapeutic drugs in milligram quantities to the lung efficiently and reproducibly. Commercial manufacturing processes exist for production of delivery systems suitable for this purpose. Generally, the deposition of small molecules in the "deep lung" leads to high absorption rates, making the inhalation delivery attractive for drugs with intended rapid onset of action. Many therapeutics, especially peptides and proteins, that cannot be delivered systemically non-invasively, are absorbed with various degrees of systemic bioavailability via inhalation. The critical factor for efficient and reproducible systemic delivery is lung deposition which depends on the properties of drug particles (size, shape, density, hygroscopicity, velocity, charge) and the state of the respiratory system (including the individual's anatomy, age, sex, disease, lung volume). While concerns exist about the potential adverse reactions of the immune system to therapeutic proteins and peptides delivered to and through the lung, there is not much data on the immune response or its link to any safety issues with inhaled biologics. Desirable systemic immune effects have been demonstrated by cytokine delivery to the lung.
Expert Opinion on Drug Delivery, 2004
Inhalation therapy is an effective way for local and systemic delivery of miscellaneous drugs for pulmonary and non-pulmonary diseases. The inhalation therapy aims to target specific cells or regions of the lung, bypassing the lung's clearance mechanisms and thereby providing high retention of the drug for longer periods. It helps in improved penetration of intravenously administered antibiotics into lung parenchymal tissue and bronchial secretions, and as a result, their potential systemic toxicity is reduced when given over prolonged periods of time. The advancement in device technology supports the development of more efficient therapy in the form of delivering finer particles into the lung in large doses. Therefore, meticulous daily management of lung disease, together with prompt, aggressive treatment of exacerbations can be achieved through inhalation to preserve lung function. This review summarizes the features of inhalation delivery devices, their advantages and limitations, challenges in formulation and brief description of novel technologies currently marketed. INTRODUCTION The pulmonary route of administration has been selected as an effective route for the treatment of pulmonary and non-pulmonary diseases. The local and systemic delivery of drugs, proteins, peptides, and biotechnology products for the treatment of various diseases can be administered through pulmonary delivery. Lungs offer a huge surface area with abundant vasculature and thin air-blood barrier. This makes pulmonary delivery very useful for rapid absorption of drugs with the additional benefit of bypassing first pass metabolism. Local administration of drugs to the lungs offers several advantages, for patients suffering from pulmonary infections, asthma, and lung cancer [1,2]. The deposition pattern and efficacy of the inhalant are dependent on the proper apportionment of the formulation factors and design of the delivery device efficacy. Thus, the success and effectiveness of inhalation therapy greatly depend on parameters such as the drug formulation, design of the inhaler device, the patient condition, and availability of the drug at the intended site of deposition [3]. Practicing of inhalation therapy has been seen over thousands of years by ancient civilizations in Egypt, Greece, India, and People's Republic of China [4]. The approaches of administration through inhalation deliver the effective dose directly to the site of disease rather than administering much higher doses systemically. Localization of therapies help in economic utilization of the drug in smaller doses thus helps in reduction in systemic side effects with elevated drug concentration at the site of action, and reduction in the frequency of administration [5]. Recently, Center for Drug Evaluation and Research and Food and Drug Administration (FDA) have approved Cayston TM an inhalation solution for antibiotic Aztreonam for the treatment of pneumonia.
The AAPS Journal, 2015
In the session on "Pharmacodynamic studies to demonstrate efficacy and safety", presentations were made on methods of evaluating airway deposition of inhaled corticosteroids and bronchodilators, and systemic exposure indirectly using pharmacodynamic study designs. For inhaled corticosteroids, limitations of measuring exhaled nitric oxide and airway responsiveness to adenosine for antiinflammatory effects were identified, whilst measurement of 18-h area under the cortisol concentration-time curve was recommended for determining equivalent systemic exposure. For bronchodilators, methacholine challenge was recommended as the most sensitive method of determining the relative amount of β-agonist or anti-muscarinic agent delivered to the airways. Whilst some agencies, such as the Food and Drug Administration (FDA), do not require measuring systemic effects when pharmacokinetic measurements are feasible, the European Medicines Agency requires measurement of heart rate and serum potassium, and some require serial electrocardiograms when bioequivalence is not established by pharmacokinetic (PK) studies. The Panel Discussion focused on whether PK would be the most sensitive marker of bioequivalence. Furthermore, there was much discussion about the FDA draft guidance for generic fluticasone propionate/salmeterol. The opinion was expressed that the study design is not capable of detecting a non-equivalent product and would require an unfeasibly large sample size.
British Journal of Clinical Pharmacology, 2003
Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.
CHEST Journal, 2013
both local and systemic. Furthermore, specifi c reaction of the airways to each type of pill strongly affects the outcome. It is crucial for pulmonologists and emergency medicine specialists to acknowledge this clinical entity. In addition, airways have been increasingly used to deliver medications such as insulin and prostacycline. These aerosolized medications can also cause local as well as systemic side effects. We review the local and systemic reactions of these "pills" accessing the airways either by incidental aspiration or iatrogenic administration. We address clinical presentation, mechanism of injury, diagnosis, and management of complications of these pills in the air passages.
Empires and Gods: The Role of Religions in Imperial History, 2024
Tel Beth-Shean in the 10th-9th Centuries BCE: a Chronological Query and its Possible Archaeomagnetic Resolution. In: Erez Ben-Yosef and Ian W. N. Jones, “And in length of days understanding” (Job 12:12) - Essays on Archaeology in the 21st Century in Honor of Thomas E. Levy. Springer Nature, pp..., 2023
In Media Res, 2017
Αρχαιολογικόν Δελτίον, 2024
Русь, Литва, Орда в памятниках нумизматики и сфрагистики. Выпуск 12, 2023
Liturgia sacra, 2022
Zeitschrift für Ästhetik und allgemeine Kunstwissenschaft, 2005
Palafittes News, 2023
The Spirit of Space Exploration in China and the West, 2024
cipa.icomos.org
African journal of science, technology and social sciences, 2024
Journal of Innovations in Cardiac Rhythm Management, 2014
Passer Journal of Basic and Applied Sciences, 2022
Toxicology and Applied Pharmacology, 1989
International Journal of Hydrogen Energy, 2015
2021